Securities Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights -

Alto Neuroscience, Inc. (NYSE: ANRO) faces a securities lawsuit after investors claimed the company made false statements about its product pipeline, ALTO-100. The lawsuit alleges that the company's product was less effective in treating major depressive disorder than investors were led to believe. As a result, investors may be eligible for a recovery under the federal securities laws.

Key Takeaways:

  • The lawsuit is filed on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Alto common stock or securities between February 2, 2024, and October 22, 2024.
  • The complaint alleges that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants claimed.
  • The lawsuit alleges that Alto's business and/or financial prospects were overstated due to the false statements about ALTO-100.
  • Investors who suffered a loss in Alto Neuroscience, Inc. stock during the relevant time frame may be eligible for a recovery.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing investors in the lawsuit.
  • The firm has a track record of securing hundreds of millions of dollars for aggrieved shareholders and has been ranked one of the top securities litigation firms in the United States for seven consecutive years.

Statistics:

  • The lawsuit covers a period of approximately 9 months, from February 2, 2024, to October 22, 2024.
  • Alto Neuroscience, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol ANRO.
  • The lawsuit alleges that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than investors were led to believe.
  • Levi & Korsinsky LLP has a team of over 70 employees to serve its clients.

Sources:

  • Newsfile Corp
  • https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=163417&wire=5&utm_campaign=26
  • Levi & Korsinsky LLP
  • Tel: (212) 363-7500
  • Fax: (212) 363-7171